AKTS Overview

Aktis Oncology, Inc. is a clinical-stage oncology company. The Company is focused on expanding the potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The Company’s proprietary mini-protein radio conjugate platform aims to safely confer efficacy to a range of patient populations. Its mini-protein radio conjugates are designed to selectively deliver the tumor-killing properties of radioisotopes to targeted tumors with high tumor penetration and prolonged retention, while being rapidly cleared from normal organs and tissues to minimize systemic radiation exposure. Its pipeline includes AKY-1189 and AKY-2519. AKY-1189, is targeting Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, colorectal cancer and cervical cancer. AKY-2519 targets B7-H3 expressing solid tumors, such as prostate, lung and breast cancers.

Wall Street analysts forecast AKTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKTS is31.67 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aktis Oncology Inc revenue for the last quarter amounts to 3.23M USD, increased 123.01

Aktis Oncology Inc. EPS for the last quarter amounts to -0.38 USD, increased 26.67

Aktis Oncology Inc (AKTS) has 79 emplpoyees as of May 31 2026.

Today AKTS has the market capitalization of 1.15B USD.